Drug Profile
Research programme: eye disorders therapeutics controlled release - NeuBase Therapeutics
Alternative Names: OHR-3031Latest Information Update: 06 Sep 2023
Price :
$50
*
At a glance
- Originator Ohr Pharmaceutical
- Developer NeuBase Therapeutics
- Class Proteins; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Allergic conjunctivitis; Glaucoma; Open-angle glaucoma; Retinal disorders
Most Recent Events
- 06 Sep 2023 Discontinued - Preclinical for Allergic conjunctivitis in USA (unspecified route)
- 06 Sep 2023 Discontinued - Preclinical for Glaucoma in USA (unspecified route)
- 06 Sep 2023 Discontinued - Preclinical for Open-angle glaucoma in USA (unspecified route)